September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, announced the acquisition of U.K.-based Imanova. Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.
Imanova’s specialty is the application of positron emission tomography (PET) and magnetic resonance (MR) imaging, with a focus on translational research to support the transition from pre-clinical studies to Phase I/II studies in humans. The services of the combined business covers the entire translational spectrum, ranging from novel biomarker evaluation and development in early discovery to late-phase clinical trials support.
For more information: www.invicro.com, www.imanova.co.uk
October 16, 2026 
